Axel Calissendorff has authored a chronicle published in the magazine of the Swedish Bar Association’s network Hilda. The chronicle analyses developments and current challenges and opportunities regarding modernisation and gender equality in the legal profession in Sweden.
Jan-Mikael Bexhed has authored an article in Swedish legal journal Svensk Juristtidning (SvJT), analysing a recent judgement from the Swedish Supreme Court regarding protection of property rights under the Swedish constitution.
Calissendorff Swarting partner Odd Swarting together with special counsel Alexander Besher and associate Johanna Forsberg, have represented the winning party in a case regarding a challenge of an arbitration award. The matter was adjudicated by the Swedish Supreme Court in a judgement rendered 20 March 2019.
We hare honored to share that five of our partners are acknowledged with top rankings within their respective field and that the firm is recognized as a leading firm within its Life Sciences practice area in the 2019 edition of Chambers Europe – a list of Europe’s best lawyers and law firms.
For the fourth consecutive year Axel Calissendorff has been appointed Chair of the Recipharm AB (publ) Nomination Committee.
Calissendorff Swarting litigation partner Einar Wanhainen has been recognized as the “2018-2019 Lawyer of the Year" award recipient by Best Lawyers for his work in Litigation in Stockholm.
Calissendorff Swarting litigation partner Einar Wanhainen has represented the winning party in a dispute adjudicated by the Swedish Supreme Court in an award rendered 13 June 2018. The dispute was about professional liability for a member of the Swedish Bar Association and will be an important precedent for other professional liability cases.
We are happy to announce that Einar Wanhainen joins Calissendorff Swarting as partner as per 1 March 2018. For more information about Einar and about the firm, please read the attached press release (in Swedish).
We are proud to announce that on the 28 of January 2018 the Royal Court announced on www.kungahuset.se that H.M. The King of Sweden has bestowed Calissendorff Swarting partner Jan-Mikael Bexhed with H.M. The King´s medal in the 8th size with the ribbon of the Order of the Seraphim.
Jan-Mikael Bexhed has co-authored an opinion column in Swedish newspaper Svenska Dagbladet regarding constitutional issues surrounding the Swedish government's proposal on limitation on profits within tax funded welfare services.
Jan-Mikael Bexhed has co-authored an opinion column in Swedish newspaper Svenska Dagbladet regarding the need for an immunity legislation for the protection of foreign works of art, to facilitate cross-border lending of art between museums.
The Supreme Administrative Court (Sw: Högsta förvaltningsdomstolen) has granted the Church of Sweden (the Diocese of Linköping) leave to appeal in a dispute between the Diocese and the National Heritage Board concerning the legal concept of a “church site” (Sw: kyrkotomt) under the Culture Heritage Act of 1988.
Jan-Mikael Bexhed has been appointed chairman of a working group of seven prominent attorneys, who will lead the work to review and revise the Swedish Bar Association's Legal Certainty Program, which was launched nearly 30 years ago
Axel Calissendorff, founding partner, has been appointed special examiner (Sw. särskild granskningsman) by the board of directors of Eltel AB (publ) to investigate potential irregularities behind the considerable need for write-downs reported by the company 21 February 2016.
Calissendorff Swarting supports Swedish Orphan Biovitrum AB (publ) (Sobi) legal department with advice and lawyers for a longer period of time. Camilla Appelgren is primarily Calissendorff Swarting’s responsible partner. The assignment involves also Peter Nilsson, Martin Nyberg and other lawyers from the firm.
Sobi is an international specialty healthcare company dedicated to rare diseases with a mission to develop and deliver innovative therapies and services to improve the lives of patients. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of businesses in India, Sweden and the United States for 1.7 billion for the creation of a leading global CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry.
Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of 74 per cent of the shares in Nitin Lifesciences Limited, an Indian family owned Contract Manufacturing Organisation (CMO) that produces sterile injectables, for a purchase price of INR 6,713 million (SEK 824 million) on a cash and debt free basis.
Calissendorff Swarting represented Aprea AB, a subsidiary of Karolinska Development AB, in a SEK 437 million financing.